-
Mashup Score: 4
PURPOSEWe conducted a phase I trial to determine the safety, tolerability, and preliminary antitumor activity of 131I-metaiodobenzylguanidine (MIBG) combined with the anti-GD2 antibody dinutuximab with or without the histone deacetylase inhibitor …
Source: ascopubs.orgCategories: General Medicine NewsTweet
-
Mashup Score: 5
The Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for PHOX2B PC-CAR T (Myrio Therapeutics, Melbourne, Aus…
Source: practicalneurology.comCategories: General Medicine News, NeurologyTweet-
The @US_FDA authorized human clinical trials to investigate Myrio Therapeutics’ investigational CAR T therapy for the treatment of #neuroblastoma. https://t.co/ziMlb8VUv0 @ChildrensPhila @neuroonc @AANmember @|ASCO
-
-
Mashup Score: 51A drug that induces the microRNA miR-124 enables differentiation of retinoic acid–resistant neuroblastoma cells - 3 month(s) ago
An alternative strategy to differentiate neuroblastoma is to induce miR-124 with the kinase inhibitor PP121.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
By offering a reliable tool to induce the differentiation of immature #neuroblastoma cells, a new @SciSignal study could inform future research into the mechanisms of high-risk neuroblastoma and the ongoing quest for treatments. https://t.co/iFlxhiLNji https://t.co/PbarYNaXEG
-
-
Mashup Score: 50A drug that induces the microRNA miR-124 enables differentiation of retinoic acid–resistant neuroblastoma cells - 3 month(s) ago
An alternative strategy to differentiate neuroblastoma is to induce miR-124 with the kinase inhibitor PP121.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
By offering a reliable tool to induce the differentiation of immature #neuroblastoma cells, a new @SciSignal study could inform future research into the mechanisms of high-risk neuroblastoma and the ongoing quest for treatments. https://t.co/iFlxhiLNji https://t.co/PbarYNaXEG
-
-
Mashup Score: 1RIST Prolongs PFS, OS in MYCN-Amplified Neuroblastoma - 10 month(s) ago
RIST improved outcomes over irinotecan-temozolomide in patients with MYCN-amplified, relapsed or refractory neuroblastoma in a phase 2 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
The combination of RIST can improve outcomes when compared to irinotecan-temozolomide only in patients with MYCN-amplified, relapsed or refractory #neuroblastoma. Published in @TheLancetOncol. https://t.co/oXF1VwciQ1
-
-
Mashup Score: 9
Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Drug targeting RNA modifications shows promise for treating #neuroblastoma @CellReports https://t.co/5EC9tAR99K
-
-
Mashup Score: 17
It’s an exciting time for research into high-risk neuroblastoma. Over the past year, multiple trials testing new treatments showed promising results, and in 2024, new trials are expected to open to further advance this research. We look at some of the latest advances and how they could change the outlook for children with neuroblastoma.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet-
Our researchers are working to find more effective, less toxic treatments for #neuroblastoma. Read about their latest advances: https://t.co/qv2Y5XdtOK Thanks to support from our donors we are speeding up the rate of progress. Make a regular gift today: https://t.co/AM5CmHkgjF https://t.co/nT2QDIK6OX
-
-
Mashup Score: 27Rally Foundation Awards $5M for a Record Number of Grants to 74 Childhood Cancer Researchers - 1 year(s) ago
This year, 51 researchers across 31 institutions worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research.
Source: rallyfoundation.orgCategories: General Medicine News, Hem/OncsTweet-
Announced today (not an April fools joke)! So thankful to the @RallyFoundation for their support for @ADurbinLab postdocs @ShendyNoha and Ian Delahunty! Both working on targeting #neuroblastoma through innovative new ways (though Noha is on hiatus). https://t.co/IuUFglsDNB
-
-
Mashup Score: 19Study successfully mimics complex neuroblastoma vasculature on a chip to explore treatments - 1 year(s) ago
Neuroblastoma, one of the most common childhood cancers, is classified as a developmental cancer because it arises prenatally during the formation of organs and tissues. It originates from cancer cells …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Study successfully mimics complex #neuroblastoma vasculature on a chip to explore treatments https://t.co/vQYtanMZbY
-
-
Mashup Score: 25Researchers discover a signaling molecule in neuroblastoma immunosuppression and aggressiveness - 1 year(s) ago
The MYCN oncoprotein (proteins related to the growth of cancer cells) plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially …
Source: medicalxpress.comCategories: General Medicine News, General NewsTweet-
Researchers discover a signaling molecule in #neuroblastoma immunosuppression and aggressiveness @BUMedicine @ScienceAdvances https://t.co/3r5W8nIIKt
-
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab 6 Vorinostat for Patients With Relapsed or Refractory #Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Learn more. https://t.co/iZtErWXKeT